PTGX

Protagonist Therapeutics Inc

Jan 27 • 04:00PM ET

83.08

+0.78 0.95 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN REGN CRSP VRTX NTLA BLUE ARWR EDIT AKRO SGMO

| Held by: IJR VTI IWM XBI VB VXF SPSM IWO IJT IBB

Index	RUT	P/E	131.17	EPS (ttm)	0.63	Insider Own	5.69%	Shs Outstand	62.45M	Perf Week	-0.41%
Market Cap	5.19B	Forward P/E	99.17	EPS next Y	0.84	Insider Trans	-5.41%	Shs Float	58.96M	Perf Month	-6.48%
Enterprise Value	4.63B	PEG	-	EPS next Q	-0.34	Inst Own	110.38%	Short Float	14.07%	Perf Quarter	10.98%
Income	45.91M	P/S	24.82	EPS this Y	-139.16%	Inst Trans	-0.49%	Short Ratio	9.16	Perf Half Y	47.67%
Sales	209.22M	P/B	8.04	EPS next Y	150.57%	ROA	7.03%	Short Interest	8.30M	Perf YTD	-4.88%
Book/sh	10.34	P/C	9.02	EPS next 5Y	-	ROE	7.80%	52W High	96.54 -13.94%	Perf Year	120.43%
Cash/sh	9.22	P/FCF	81.52	EPS past 3/5Y	- -	ROIC	7.02%	52W Low	33.70 146.53%	Perf 3Y	612.52%
Dividend Est.	-	EV/EBITDA	225.56	Sales past 3/5Y	151.35% 351.71%	Gross Margin	99.28%	Volatility	3.77% 3.69%	Perf 5Y	238.27%
Dividend TTM	-	EV/Sales	22.12	EPS Y/Y TTM	-72.97%	Oper. Margin	9.09%	ATR (14)	3.11	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.05	Sales Y/Y TTM	-35.39%	Profit Margin	21.94%	RSI (14)	46.33	Recom	1.23
Dividend Gr. 3/5Y	- -	Current Ratio	13.05	EPS Q/Q	-14.73%	SMA20	-0.69%	Beta	2.26	Target Price	95.92
Payout	0.00%	Debt/Eq	0.02	Sales Q/Q	0.79%	SMA50	-3.73%	Rel Volume	0.56	Prev Close	82.30
Employees	126	LT Debt/Eq	0.01	Earnings	Nov 06 AMC	SMA200	28.32%	Avg Volume	906.02K	Price	83.08
IPO	Aug 11, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.10% 31.51%	Trades		Volume	507,807	Change	0.95%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-17-25	Initiated	Barclays	Overweight	$72
Sep-12-25	Initiated	Leerink Partners	Outperform	$73
Jun-17-25	Initiated	Citigroup	Buy	$72
Dec-06-24	Initiated	Goldman	Neutral	$47
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$62
Nov-05-24	Initiated	Wedbush	Outperform	$58
Sep-24-24	Initiated	TD Cowen	Buy	$65
Sep-09-24	Initiated	Truist	Buy	$60
Oct-30-23	Initiated	CapitalOne	Overweight	$32
May-25-23	Resumed	Jefferies	Buy	$30 → $40
Aug-25-22	Initiated	JMP Securities	Mkt Outperform	$21
Feb-11-22	Initiated	BTIG Research	Buy	$55
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight	$49 → $55
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform	$40
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral	$60 → $49
May-24-21	Initiated	Northland Capital	Outperform	$42
May-24-21	Initiated	JMP Securities	Mkt Outperform	$48
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight	$53
Sep-18-20	Reiterated	H.C. Wainwright	Buy	$28 → $33

Show Previous Ratings

Jan-07-26 07:30AM	Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 (ACCESSWIRE)
Jan-06-26 04:29PM	Alumis Stock Catapults More Than 95% As Biotech Takes On J&J, Protagonist In Psoriasis (Investor's Business Daily)
07:05AM	Takeda and Protagonist seek FDA approval for rusfertide to treat PV (Pharmaceutical Technology)
Jan-05-26 07:00AM	Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) (Business Wire)
Dec-06-25 09:30AM	Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera (Business Wire)
04:21PM	Loading…
Dec-05-25 04:21PM	Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory (Insider Monkey)
Nov-27-25 03:45AM	Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice (ACCESSWIRE)
Nov-06-25 05:45PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:42PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-04-25 10:00AM	Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-03-25 04:05PM	Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting (ACCESSWIRE)
Oct-30-25 10:00AM	Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-28-25 07:40AM	Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
07:35AM	Loading…
Oct-27-25 07:35AM	Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences (ACCESSWIRE)
Oct-18-25 12:04PM	Johnson & Johnson's M&A Strategy Is the Real Story for Investors (MarketBeat)
Oct-13-25 02:50PM	Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal (Zacks) -9.00%
06:46AM	J&J in talks to acquire Protagonist Therapeutics (Pharmaceutical Technology)
Oct-10-25 07:07PM	Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today (Motley Fool) +29.77%
02:21PM	Trump's China tariff threat sinks stocks, Applied Digital surges (Yahoo Finance Video)
01:38PM	RTW Investments' Rod Wong: Expect more deals in biotech space (CNBC TV)
11:53AM	Protagonist Therapeutics stock surges after J&J acquisition talks report (Investing.com)
11:23AM	Protagonist Stock Surges on Johnson & Johnson Report (The Wall Street Journal)
11:13AM	Johnson & Johnson in Talks to Buy Protagonist Therapeutics (The Wall Street Journal)
10:23AM	Stock Market Today: Market Tumbles After Trump Threatens "Massive Increase" on China Tariffs (TheStreet)
Oct-07-25 08:10AM	Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill (ACCESSWIRE)
Sep-17-25 11:45AM	Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory (Insider Monkey)
08:00AM	Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress (ACCESSWIRE)
Sep-15-25 10:45AM	Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 (ACCESSWIRE)
11:36AM	Loading…
Sep-12-25 11:36AM	JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra (Zacks)
Sep-11-25 08:00AM	Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency (ACCESSWIRE)
Aug-26-25 04:05PM	Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 (ACCESSWIRE) +7.79%
Aug-25-25 07:00AM	Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera (ACCESSWIRE)
Aug-06-25 05:25PM	Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.39%
04:24PM	Protagonist Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Jul-22-25 11:51AM	JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra (Zacks)
Jul-21-25 08:05AM	Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis (ACCESSWIRE)
Jun-30-25 04:09PM	Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? (Investor's Business Daily) -9.16%
04:05PM	Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity (ACCESSWIRE)
Jun-26-25 07:05AM	Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate (ACCESSWIRE)
Jun-24-25 03:09PM	Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera (Insider Monkey)
Jun-23-25 01:17PM	Zeta (ZETA) Surges 12.6%: Is This an Indication of Further Gains? (Zacks)
09:07AM	Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? (Zacks)
Jun-17-25 12:57PM	Citi initiates coverage on biotech amid improving sentiment in sector (Investing.com)
Jun-09-25 10:00AM	For Patients With Rare Blood Cancer, New Drug Offers Relief (The Wall Street Journal)
Jun-01-25 08:00AM	Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera (Business Wire)
May-27-25 09:29AM	Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome (Insider Monkey)
May-21-25 07:05AM	Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 (ACCESSWIRE)
May-12-25 08:11AM	J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study (Zacks) +5.35%
May-09-25 10:27AM	Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey)
08:05AM	Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting (ACCESSWIRE)
May-06-25 06:30PM	Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -5.13%
04:05PM	Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Apr-23-25 10:35AM	Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 (ACCESSWIRE)
Apr-10-25 08:10AM	Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill (ACCESSWIRE)
Apr-01-25 02:27PM	Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns (Seeking Alpha)
Mar-25-25 09:55AM	Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? (Zacks)
Mar-18-25 02:10PM	Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) Best Biotech Stock for 2025? (Insider Monkey)
07:00AM	These 10 biotech companies are changing how we discover new drugs and treat complex diseases (FastCompany)
07:00AM	Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 (ACCESSWIRE)
Mar-15-25 04:40PM	Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? (Insider Monkey)
Mar-12-25 12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why (Zacks)
Mar-11-25 09:29AM	Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success (GuruFocus.com) +6.81%
08:37AM	J&J and Protagonists icotrokinra scores in Phase IIb UC study (Clinical Trials Arena)
06:47AM	Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday (Insider Monkey)
Mar-10-25 04:30PM	Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out (Investor's Business Daily) +45.89%
08:15AM	Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis (ACCESSWIRE)
Mar-08-25 09:15AM	Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis (ACCESSWIRE)
Mar-03-25 12:01PM	Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer (Benzinga)
10:25AM	Takeda and Protagonist report topline outcomes from trial of rusfertide (Clinical Trials Arena)
06:45AM	Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera (Business Wire)
06:29AM	Protagonist says Takeda-partnered drug succeeds in rare blood cancer (BioPharma Dive)
Feb-21-25 08:35AM	Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates (Zacks)
07:34AM	Protagonist Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Feb-12-25 07:51AM	Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Jan-31-25 07:00AM	Biotech walks a 'tightrope' amid unclear funding, regulations (Yahoo Finance Video)
Jan-29-25 06:15PM	Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025 (ACCESSWIRE)
Jan-06-25 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Dec-19-24 04:05PM	Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 (ACCESSWIRE)
Dec-09-24 04:05PM	Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting (ACCESSWIRE)
Dec-06-24 06:48AM	Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities (TipRanks)
Nov-22-24 07:30AM	Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024 (ACCESSWIRE) +11.55%
Nov-21-24 04:05PM	Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate (ACCESSWIRE)
Nov-19-24 07:30AM	Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate (ACCESSWIRE)
Nov-18-24 04:30PM	Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor (ACCESSWIRE)
Nov-13-24 12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-07-24 05:30PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:56PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-05-24 04:05PM	Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting (ACCESSWIRE)
Oct-29-24 09:27AM	Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million (ACCESSWIRE)
Oct-18-24 06:28AM	Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases (Insider Monkey)
Oct-16-24 03:03PM	State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc (GuruFocus.com)
Sep-10-24 01:17PM	Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines (Benzinga)
Sep-03-24 07:30AM	Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 (ACCESSWIRE)
Aug-06-24 01:53PM	PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace)
08:20AM	Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PATEL DINESH V PH D	President and CEO	Jan 26 '26	Option Exercise	14.12	24,890	351,528	588,710	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 27 '26	Option Exercise	21.58	4,068	87,787	578,573	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 23 '26	Option Exercise	4.21	19,315	81,316	593,820	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 26 '26	Sale	84.03	24,890	2,091,470	574,505	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 23 '26	Sale	84.59	19,315	1,633,856	574,505	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 27 '26	Sale	83.19	4,068	338,417	574,505	Jan 27 09:21 PM
Ali Asif	Chief Financial Officer	Jan 27 '26	Option Exercise	16.18	28,000	453,080	106,523	Jan 27 09:20 PM
Ali Asif	Chief Financial Officer	Jan 27 '26	Sale	83.13	46,203	3,841,037	60,320	Jan 27 09:20 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 27 '26	Option Exercise	8.04	5,000	40,200	89,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 26 '26	Option Exercise	8.04	5,000	40,200	89,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 23 '26	Sale	82.42	13,151	1,083,905	84,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 26 '26	Sale	82.28	5,000	411,400	84,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 27 '26	Sale	82.00	5,000	410,000	84,115	Jan 27 09:19 PM
ASIF ALI	Officer	Jan 27 '26	Proposed Sale	83.14	46,203	3,841,128		Jan 27 05:12 PM
ARTURO MOLINA	Officer	Jan 27 '26	Proposed Sale	82.00	5,000	410,000		Jan 27 04:01 PM
ARTURO MOLINA	Officer	Jan 26 '26	Proposed Sale	82.28	5,000	411,396		Jan 26 04:29 PM
ARTURO MOLINA	Officer	Jan 23 '26	Proposed Sale	83.42	13,151	1,097,116		Jan 23 04:32 PM
Dinesh Patel	CEO	Jan 23 '26	Proposed Sale	84.62	108,273	9,162,061		Jan 23 04:06 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 20 '26	Sale	82.48	9,514	784,715	97,266	Jan 21 05:17 PM
PATEL DINESH V PH D	President and CEO	Jan 20 '26	Sale	82.48	34,438	2,840,446	580,505	Jan 21 05:16 PM
Ali Asif	Chief Financial Officer	Jan 20 '26	Sale	82.48	8,588	708,338	78,077	Jan 21 05:15 PM
ARTURO MOLINA MD	Officer	Jan 20 '26	Proposed Sale	82.48	9,514	784,715		Jan 21 05:12 PM
DINESH V PATEL PH D	Officer, Director	Jan 20 '26	Proposed Sale	82.48	34,438	2,840,446		Jan 21 05:11 PM
Asif Ali	Officer	Jan 20 '26	Proposed Sale	82.48	8,588	708,338		Jan 21 05:10 PM
SELICK HAROLD E	Director	Jan 09 '26	Option Exercise	4.21	14,299	60,199	60,845	Jan 13 04:45 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 17 '25	Sale	84.77	2,712	229,896	81,180	Nov 19 04:01 PM
Waddill William D.	Director	Oct 10 '25	Option Exercise	6.98	12,000	83,760	17,130	Oct 14 04:01 PM
Waddill William D.	Director	Oct 10 '25	Sale	81.62	12,000	979,480	5,130	Oct 14 04:01 PM
WILLIAM WADDILL	Director	Oct 10 '25	Proposed Sale	67.04	12,000	804,480		Oct 10 04:18 PM
Waddill William D.	Director	Sep 22 '25	Sale	64.25	4,000	257,000	5,130	Sep 24 08:35 PM
WILLIAM WADDILL	Director	Sep 22 '25	Proposed Sale	62.20	4,000	248,800		Sep 22 04:27 PM
Waddill William D.	Director	Aug 27 '25	Sale	59.25	4,000	237,000	9,130	Aug 29 05:30 PM
WILLIAM WADDILL	Director	Aug 27 '25	Proposed Sale	56.99	4,000	227,960		Aug 27 04:33 PM
PATEL DINESH V PH D	President and CEO	Jul 25 '25	Sale	54.78	10,415	570,534	520,603	Jul 28 06:08 PM
PATEL DINESH V PH D	President and CEO	Jul 22 '25	Sale	55.05	22,065	1,214,678	548,538	Jul 23 06:57 PM
PATEL DINESH V PH D	President and CEO	Jul 23 '25	Sale	54.79	17,520	959,921	531,018	Jul 23 06:57 PM
PATEL DINESH V PH D	President and CEO	Jul 21 '25	Sale	54.86	12,859	705,445	570,603	Jul 23 06:57 PM
Dinesh Patel	CEO	Jul 22 '25	Proposed Sale	55.22	50,000	2,761,000		Jul 22 04:04 PM
MOLINA ARTURO MD	Chief Medical Officer	Jun 09 '25	Option Exercise	8.04	10,000	80,400	93,892	Jun 11 05:40 PM
MOLINA ARTURO MD	Chief Medical Officer	Jun 10 '25	Option Exercise	8.04	10,000	80,400	93,892	Jun 11 05:40 PM
MOLINA ARTURO MD	Chief Medical Officer	Jun 10 '25	Sale	57.03	10,000	570,300	83,892	Jun 11 05:40 PM
MOLINA ARTURO MD	Chief Medical Officer	Jun 09 '25	Sale	55.51	10,000	555,100	83,892	Jun 11 05:40 PM
ARTURO MOLINA	Officer	Jun 10 '25	Proposed Sale	57.03	10,000	570,269		Jun 10 05:51 PM
ARTURO MOLINA	Officer	Jun 09 '25	Proposed Sale	55.51	10,000	555,077		Jun 09 04:46 PM
SELICK HAROLD E	Director	Apr 28 '25	Option Exercise	1.16	10,725	12,441	43,851	Apr 30 04:45 PM
Ali Asif	Chief Financial Officer	Apr 22 '25	Sale	46.00	1,756	80,776	61,065	Apr 23 04:30 PM
Waddill William D.	Director	Mar 17 '25	Sale	54.25	4,000	217,000	13,130	Mar 19 04:01 PM
WILLIAM D WADDILL	Director	Mar 17 '25	Proposed Sale	54.78	4,000	219,120		Mar 17 04:30 PM
MOLINA ARTURO MD	Chief Medical Officer	Mar 13 '25	Option Exercise	24.48	30,514	746,956	114,406	Mar 14 06:21 PM
MOLINA ARTURO MD	Chief Medical Officer	Mar 13 '25	Sale	55.74	30,514	1,700,850	83,892	Mar 14 06:21 PM
Ali Asif	Chief Financial Officer	Mar 12 '25	Option Exercise	14.90	24,903	371,164	87,724	Mar 14 06:20 PM
Ali Asif	Chief Financial Officer	Mar 12 '25	Sale	58.73	24,903	1,462,553	62,821	Mar 14 06:20 PM
MOLINA ARTURO MD	Officer	Mar 13 '25	Proposed Sale	55.00	30,514	1,678,270		Mar 13 05:24 PM
Ali Asif	Officer	Mar 12 '25	Proposed Sale	58.73	24,903	1,462,587		Mar 12 05:31 PM
PATEL DINESH V PH D	President and CEO	Mar 05 '25	Option Exercise	4.21	24,000	101,040	564,260	Mar 05 08:02 PM
PATEL DINESH V PH D	President and CEO	Feb 19 '25	Sale	38.18	5,359	204,607	540,260	Feb 20 05:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTGX

Protagonist Therapeutics Inc

Upgrade your FINVIZ experience